The Integra LifeSciences Holdings Corp.’s (IART) “Sector Perform” Rating Reaffirmed at RBC Capital Markets

The Integra LifeSciences Holdings Corp.’s (IART) “Sector Perform” Rating Reaffirmed at RBC Capital Markets

RBC Capital Markets reiterated their sector perform rating on shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) in a report issued on Friday morning. The brokerage currently has a $46.00 price target on the stock, down from their previous price target of $85.00.

IART has been the subject of several other research reports. Royal Bank Of Canada dropped their price objective on Integra LifeSciences Holdings Corp. from $85.00 to $46.00 and set a sector perform rating for the company in a research note on Friday, January 13th. JMP Securities raised Integra LifeSciences Holdings Corp. from a market perform rating to an outperform rating and set a $50.00 price objective for the company in a research note on Friday, January 6th. Oppenheimer Holdings Inc. reissued a buy rating on shares of Integra LifeSciences Holdings Corp. in a research note on Wednesday, January 11th. Argus lifted their price objective on Integra LifeSciences Holdings Corp. from $45.00 to $52.50 and gave the company a buy rating in a research note on Friday, September 23rd. Finally, Zacks Investment Research lowered Integra LifeSciences Holdings Corp. from a buy rating to a hold rating in a research note on Friday, January 6th. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Integra LifeSciences Holdings Corp. currently has an average rating of Buy and a consensus target price of $47.15.

Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) opened at 42.69 on Friday. The firm has a market cap of $3.19 billion, a PE ratio of 55.59 and a beta of 0.75. The stock has a 50 day moving average price of $70.34 and a 200 day moving average price of $79.72. Integra LifeSciences Holdings Corp. has a 52 week low of $41.95 and a 52 week high of $88.86.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last announced its quarterly earnings results on Thursday, October 27th. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.89 by $0.04. The company earned $250.30 million during the quarter, compared to analysts’ expectations of $249.30 million. Integra LifeSciences Holdings Corp. had a return on equity of 16.11% and a net margin of 6.09%. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 earnings per share. Equities analysts expect that Integra LifeSciences Holdings Corp. will post $1.75 earnings per share for the current year.

In other news, CEO Peter J. Arduini sold 24,009 shares of the business’s stock in a transaction dated Tuesday, November 8th. The stock was sold at an average price of $79.51, for a total value of $1,908,955.59. Following the completion of the sale, the chief executive officer now owns 25,593 shares of the company’s stock, valued at approximately $2,034,899.43. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 21.40% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. bought a new stake in Integra LifeSciences Holdings Corp. during the third quarter worth $63,680,000. RS Investment Management Co. LLC bought a new stake in Integra LifeSciences Holdings Corp. during the second quarter worth $56,604,000. Capital Research Global Investors bought a new stake in Integra LifeSciences Holdings Corp. during the second quarter worth $40,759,000. Columbus Circle Investors bought a new stake in Integra LifeSciences Holdings Corp. during the second quarter worth $31,541,000. Finally, Massachusetts Financial Services Co. MA bought a new stake in Integra LifeSciences Holdings Corp. during the second quarter worth $26,428,000. 44.10% of the stock is owned by institutional investors.

About Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

Related posts

Leave a Comment